A notable case report highlighted a dramatic response to mTOR-targeted therapy in a patient with intrahepatic cholangiocarcinoma harboring TSC1 and ARID1A mutations, indicating potential oncogenic dependence on mTOR in certain subtypes [62]. This evidence concerns the gene ARID1A and cholangiocarcinoma.